KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
Disease-free survival
KRAS mutation
Ovarian serous borderline tumor
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
20
03
2023
accepted:
16
05
2023
revised:
05
05
2023
medline:
10
7
2023
pubmed:
23
5
2023
entrez:
23
5
2023
Statut:
ppublish
Résumé
Oncogenic activation of the mitogen-activated protein kinase (MAPK) pathway due to KRAS or BRAF gain-of-function mutation is frequently found in ovarian serous borderline tumor (SBT) and their extraovarian implants. We investigated mutational status of KRAS and BRAF of the primary ovarian SBTs that had a high stage presentation in correlation with clinical outcome. Among 39 consecutive primary SBTs with either invasive implants (20 cases) or non-invasive implants (19 cases), KRAS and BRAF mutational analysis was informative in 34 cases. Sixteen cases (47%) harbored a KRAS mutation, while 5 cases (15%) had a BRAF V600E mutation. High-stage disease (IIIC) was seen in 31% (5/16) of patients with a KRAS mutation and 39% (7/18) of patients without a KRAS mutation (p = 0.64). KRAS mutations were present in 9/16 (56%) tumors with invasive implants/LGSC versus 7/18 (39%) tumors with non-invasive implants (p = 0.31). BRAF mutation was seen in 5 cases with non-invasive implants. Tumor recurrence was seen in 31% (5/16) of patients with a KRAS mutation, compared to 6% (1/18) of patients without a KRAS mutation (p = 0.04). A KRAS mutation predicted an adverse disease-free survival (31% survival at 160 months) compared to those with wild-type KRAS (94% at 160 months; log-rank test, p = 0.037; HR 4.47). In conclusion, KRAS mutation in primary ovarian SBTs is significantly associated with a worse disease-free survival, independent of the high tumor stage or histological subtypes of extraovarian implant. KRAS mutation testing of primary ovarian SBT may servce as a useful biomarker for tumor recurrence.
Identifiants
pubmed: 37219599
doi: 10.1007/s00428-023-03564-z
pii: 10.1007/s00428-023-03564-z
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
KRAS protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-79Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bell KA, Smith Sehdev AE, Kurman RJ (2001) Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol 25:419–432
doi: 10.1097/00000478-200104000-00001
pubmed: 11257616
Ahn G, Folkins AK, McKenney JK et al (2016) Low-grade serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion. Am J Surg Pathol 40:1165–1176
doi: 10.1097/PAS.0000000000000693
pubmed: 27487741
Ayhan A, Guvendag Guven ES, Guven S et al (2005) Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol 98:439–445
doi: 10.1016/j.ygyno.2005.05.033
pubmed: 16009407
Park JY, Kim DY, Kim JH et al (2009) Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol 113:75–82
doi: 10.1016/j.ygyno.2008.12.034
pubmed: 19171373
Hannibal CG, Vang R, Junge J et al (2014) A nationwide study of serous “borderline” ovarian tumors in Denmark 1978–2002: centralized pathology review and overall survival compared with the general population. Gynecol Oncol 134:267–273
doi: 10.1016/j.ygyno.2014.06.002
pubmed: 24924123
pmcid: 4370179
Longacre TA, McKenney JK, Tazelaar HD et al (2005) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 29:707–723
doi: 10.1097/01.pas.0000164030.82810.db
pubmed: 15897738
Vang R, Hannibal CG, Junge J et al (2017) Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and noninvasive low-grade carcinomas: a population-based clinicopathologic study of 942 cases. Am J Surg Pathol 41:725–737
doi: 10.1097/PAS.0000000000000824
pubmed: 28248817
pmcid: 5423818
McKenney JK, Balzer BL, Longacre TA (2006) Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am J Surg Pathol 30:614–624
doi: 10.1097/01.pas.0000194743.33540.e6
pubmed: 16699316
Seidman JD, Kurman RJ (2000) Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31:539–557
doi: 10.1053/hp.2000.8048
pubmed: 10836293
Prat J, De Nictolis M (2002) Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 26:1111–1128
doi: 10.1097/00000478-200209000-00002
pubmed: 12218568
Bell DA, Longacre TA, Prat J et al (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35:934–948
doi: 10.1016/j.humpath.2004.03.005
pubmed: 15297961
Hannibal CG, Vang R, Junge J et al (2017) A nationwide study of ovarian serous borderline tumors in Denmark 1978–2002. Risk of recurrence, and development of ovarian serous carcinoma. Gynecol Oncol 144:174–180
doi: 10.1016/j.ygyno.2016.11.007
pubmed: 27836204
Chui MH, Xing D, Zeppernick F et al (2019) Clinicopathologic and molecular features of paired cases of metachronous ovarian serous borderline tumor and subsequent serous carcinoma. Am J Surg Pathol 43:1462–1472
doi: 10.1097/PAS.0000000000001325
pubmed: 31343420
pmcid: 6786947
Singer G, Oldt R 3rd, Cohen Y et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484–486
doi: 10.1093/jnci/95.6.484
pubmed: 12644542
Ho CL, Kurman RJ, Dehari R et al (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64:6915–6918
doi: 10.1158/0008-5472.CAN-04-2067
pubmed: 15466181
Jones S, Wang TL, Kurman RJ et al (2012) Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226:413–420
doi: 10.1002/path.3967
pubmed: 22102435
Hunter SM, Anglesio MS, Ryland GL et al (2015) Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 6:37663–37677
doi: 10.18632/oncotarget.5438
pubmed: 26506417
pmcid: 4741956
Krzystyniak J, Ceppi L, Dizon DS et al (2016) Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer. Ann Oncol 27(Suppl 1):i4–i10
doi: 10.1093/annonc/mdw083
pubmed: 27141069
pmcid: 4852274
Anglesio MS, Arnold JM, George J et al (2008) Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 6:1678–1690
doi: 10.1158/1541-7786.MCR-08-0193
pubmed: 19010816
pmcid: 6953412
Xing D, Suryo Rahmanto Y, Zeppernick F et al (2017) Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. Hum Pathol 68:87–91
doi: 10.1016/j.humpath.2017.08.021
pubmed: 28873354
pmcid: 5696063
Zuo T, Wong S, Buza N et al (2018) KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Mod Pathol 31:350–357
doi: 10.1038/modpathol.2017.121
pubmed: 29027536
Chui MH, Kjaer SK, Frederiksen K et al (2019) BRAF(V600E) -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. Oncotarget 10:6870–6878
doi: 10.18632/oncotarget.27326
pubmed: 31839880
pmcid: 6901340
Tsang YT, Deavers MT, Sun CC et al (2013) KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 231:449–456
doi: 10.1002/path.4252
pubmed: 24549645
pmcid: 4095747
WHO (2020) Classification of Tumours 5th Edition - Female Genital Tumours. (IARC Press, Lyon, France
Zhong H, Liu Y, Talmor M et al (2013) Deparaffinization and lysis by hydrothermal pressure (pressure cooking) coupled with chaotropic salt column purification: a rapid and efficient method of DNA extraction from formalin-fixed paraffin-embedded tissue. Diagn Mol Pathol 22:52–58
doi: 10.1097/PDM.0b013e318263f092
pubmed: 23370427
Dillon DA, Johnson CC, Topazian MD et al (2000) The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasma. Cancer J 6:294–301
pubmed: 11079168
Metzker ML (2005) Emerging technologies in DNA sequencing. Genome Res 15:1767–1776
doi: 10.1101/gr.3770505
pubmed: 16339375
Mayr D, Hirschmann A, Löhrs U et al (2006) KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103:883–887
doi: 10.1016/j.ygyno.2006.05.029
pubmed: 16806438
Ardighieri L, Zeppernick F, Hannibal CG et al (2014) Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. J Pathol 232:16–22
doi: 10.1002/path.4293
pubmed: 24307542
pmcid: 4086471
Gershenson DM, Sun CC, Westin SN et al (2022) The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol 165:560–567
doi: 10.1016/j.ygyno.2021.11.019
pubmed: 35606067
Malpica A, Wong KK (2016) The molecular pathology of ovarian serous borderline tumors. Ann Oncol 27(Suppl 1):i16–i19
doi: 10.1093/annonc/mdw089
pubmed: 27141064
pmcid: 4852276
Silva EG, Tornos C, Zhuang Z et al (1998) Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol 17:1–6
doi: 10.1097/00004347-199801000-00001
pubmed: 9475184
Grisham RN, Iyer G, Garg K et al (2013) BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 119:548–554
doi: 10.1002/cncr.27782
pubmed: 22930283
Wong KK, Tsang YT, Deavers MT et al (2010) BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 177:1611–1617
doi: 10.2353/ajpath.2010.100212
pubmed: 20802181
pmcid: 2947258
Zeppernick F, Ardighieri L, Hannibal CG et al (2014) BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol 38:1603–1611
doi: 10.1097/PAS.0000000000000313
pubmed: 25188864
pmcid: 4314953